Q-omics provides the consensus-scored TRABD profile across patient tissues and cancer cell-line models. TRABD expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRABD is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TRABD RNA expression shows 18,492 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where TRABD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRABD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRABD survival associations across molecular data types. TRABD RNA expression shows survival associations in the most cancer types (31), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRABD RNA expression–survival associations across cancer types. High TRABD expression shows unfavorable associations in KIRC, ACC, UVM, LIHC and OV, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRABD RNA expression.
This table summarizes TRABD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRABD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRABD shows higher tumor expression in COAD, HNSC, KIRC, LIHC, STAD and UCEC. The COAD box plot shows higher TRABD RNA expression in tumor versus normal tissue (log2 FC = +1.219, t-test p < 0.001).
This table shows molecular features associated with TRABD in patient tissues and cancer cell lines. In patient samples, TRABD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRABD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
